LT2914264T - 6-okso-1,6-dihidro-piridazino darinys, skirtas naudoti hepatoceliulinės karcinomos (hcc) gydymui - Google Patents

6-okso-1,6-dihidro-piridazino darinys, skirtas naudoti hepatoceliulinės karcinomos (hcc) gydymui

Info

Publication number
LT2914264T
LT2914264T LTEP13776720.8T LT13776720T LT2914264T LT 2914264 T LT2914264 T LT 2914264T LT 13776720 T LT13776720 T LT 13776720T LT 2914264 T LT2914264 T LT 2914264T
Authority
LT
Lithuania
Prior art keywords
hcc
dihydro
oxo
treatment
hepatocellular carcinoma
Prior art date
Application number
LTEP13776720.8T
Other languages
English (en)
Lithuanian (lt)
Inventor
Manja FRIESE-HAMIM
Friedhelm BLADT
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of LT2914264T publication Critical patent/LT2914264T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Plural Heterocyclic Compounds (AREA)
LTEP13776720.8T 2012-11-02 2013-10-04 6-okso-1,6-dihidro-piridazino darinys, skirtas naudoti hepatoceliulinės karcinomos (hcc) gydymui LT2914264T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12007494 2012-11-02
PCT/EP2013/002998 WO2014067610A1 (en) 2012-11-02 2013-10-04 A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of hepatocellular carcinoma (hcc)

Publications (1)

Publication Number Publication Date
LT2914264T true LT2914264T (lt) 2017-11-10

Family

ID=47143496

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP13776720.8T LT2914264T (lt) 2012-11-02 2013-10-04 6-okso-1,6-dihidro-piridazino darinys, skirtas naudoti hepatoceliulinės karcinomos (hcc) gydymui

Country Status (26)

Country Link
US (1) US20150283137A1 (cg-RX-API-DMAC10.html)
EP (1) EP2914264B1 (cg-RX-API-DMAC10.html)
JP (1) JP6255028B2 (cg-RX-API-DMAC10.html)
KR (1) KR102131588B1 (cg-RX-API-DMAC10.html)
CN (1) CN104768553A (cg-RX-API-DMAC10.html)
AR (1) AR093318A1 (cg-RX-API-DMAC10.html)
AU (1) AU2013339823B2 (cg-RX-API-DMAC10.html)
BR (1) BR112015008279A2 (cg-RX-API-DMAC10.html)
CA (1) CA2890273C (cg-RX-API-DMAC10.html)
DK (1) DK2914264T3 (cg-RX-API-DMAC10.html)
ES (1) ES2646913T3 (cg-RX-API-DMAC10.html)
HK (1) HK1211869A1 (cg-RX-API-DMAC10.html)
HR (1) HRP20171295T1 (cg-RX-API-DMAC10.html)
HU (1) HUE035483T2 (cg-RX-API-DMAC10.html)
IL (1) IL238536B (cg-RX-API-DMAC10.html)
LT (1) LT2914264T (cg-RX-API-DMAC10.html)
MX (1) MX354518B (cg-RX-API-DMAC10.html)
NO (1) NO2914264T3 (cg-RX-API-DMAC10.html)
PL (1) PL2914264T3 (cg-RX-API-DMAC10.html)
PT (1) PT2914264T (cg-RX-API-DMAC10.html)
RS (1) RS56485B1 (cg-RX-API-DMAC10.html)
RU (1) RU2650679C2 (cg-RX-API-DMAC10.html)
SG (1) SG11201503214YA (cg-RX-API-DMAC10.html)
SI (1) SI2914264T1 (cg-RX-API-DMAC10.html)
WO (1) WO2014067610A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201503924B (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016002932B1 (pt) 2013-08-14 2021-02-23 Yugenkaisha Japan Tsusyo sistema de cultivo hidropônico
HRP20231548T1 (hr) * 2019-07-10 2024-03-15 Merck Patent Gmbh Farmaceutski pripravak
EP4045009A4 (en) 2019-10-14 2023-11-01 Olatec Therapeutics LLC METHOD FOR TREATING BREAST CANCER

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005057924A1 (de) * 2005-12-05 2007-06-06 Merck Patent Gmbh Pyridazinonderivate
DE102007032507A1 (de) * 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
CA2949515C (en) * 2009-01-08 2018-10-23 Axel Becker Polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof

Also Published As

Publication number Publication date
CN104768553A (zh) 2015-07-08
MX2015005265A (es) 2015-07-17
MX354518B (es) 2018-03-08
RS56485B1 (sr) 2018-01-31
RU2015120692A (ru) 2016-12-27
JP2015536957A (ja) 2015-12-24
CA2890273A1 (en) 2014-05-08
ZA201503924B (en) 2020-11-25
DK2914264T3 (en) 2017-09-11
SG11201503214YA (en) 2015-05-28
EP2914264B1 (en) 2017-08-09
IL238536A0 (en) 2015-06-30
HK1211869A1 (en) 2016-06-03
EP2914264A1 (en) 2015-09-09
BR112015008279A2 (pt) 2017-07-04
KR20150079942A (ko) 2015-07-08
SI2914264T1 (sl) 2017-12-29
PL2914264T3 (pl) 2017-12-29
AR093318A1 (es) 2015-05-27
HRP20171295T1 (hr) 2017-10-20
ES2646913T3 (es) 2017-12-18
RU2650679C2 (ru) 2018-04-17
KR102131588B1 (ko) 2020-07-08
NO2914264T3 (cg-RX-API-DMAC10.html) 2018-01-06
IL238536B (en) 2019-01-31
AU2013339823A1 (en) 2015-06-18
US20150283137A1 (en) 2015-10-08
WO2014067610A1 (en) 2014-05-08
AU2013339823B2 (en) 2018-01-04
HUE035483T2 (hu) 2018-05-02
CA2890273C (en) 2021-10-26
PT2914264T (pt) 2017-11-14
JP6255028B2 (ja) 2017-12-27

Similar Documents

Publication Publication Date Title
EP3685870B8 (en) Zone heating for respiratory circuits
GB201223466D0 (en) Time-based authentication
LT2552438T (lt) Hepatoceliulinės karcinomos gydymo būdai
PT2890257T (pt) Inalador
IL235825A0 (en) inhaler
AU345542S (en) Inhaler
ZA201307476B (en) New pyridazinone and pyridone compounds
EP3107538A4 (en) Combination therapy for hepatocellular carcinoma
GB2515783B (en) Process for preparing clomazone, a form and use of the same
IL235693B (en) Biological therapy for the treatment of a malignant tumor of liver cells
GB2521289B (en) Formation treatment system
PL2954114T3 (pl) Płyta do obróbki dla urządzenia do obróbki odzieży
ZA201503924B (en) A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of hepatocellular carcinoma (hcc)
GB201307348D0 (en) Garment for therapeutic treatment
SG11201605501RA (en) A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of renal cell carcinoma (rcc)
GB2553253B (en) A form of clomazone, a process for preparing the same and use of the same
GB201319234D0 (en) Method for diagnosing hepatocellular carcinoma (HCC)
GB201212604D0 (en) New treatment
GB201215527D0 (en) Compounds for the treatment of muscular dystrophy
GB201108311D0 (en) The grabbgo. Hot hand protector